Research programme: adenosine receptor antagonists - Merck/ Domain Therapeutics

Drug Profile

Research programme: adenosine receptor antagonists - Merck/ Domain Therapeutics

Alternative Names: immuno oncology therapeutics - Merck/Domain Therapeutics

Latest Information Update: 08 Feb 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Domain Therapeutics
  • Developer Domain Therapeutics; Merck KGaA
  • Class Antineoplastics; Immunotherapies; Small molecules
  • Mechanism of Action Purinergic P1 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Cancer

Most Recent Events

  • 23 Jan 2017 Early research in Cancer in France (Parenteral)
  • 23 Jan 2017 Early research in Cancer in Germany (Parenteral)
  • 23 Jan 2017 Domain Therapeutics and Merck agree to co-develop adenosine receptor antagonists for Cancer
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top